- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02763943
Improving Medication Safety and CVD Risk Factor Control in Kidney Transplant Recipients
Improving Medication Safety and Cardiovascular Risk Factor Control in Kidney Transplant Recipients
There is a lack of data analyzing the influence of Cardio-vascular Diseases (CVD) risk factor control on graft survival disparities in Black transplant recipients. Studies in the general population indicate that CVD risk factor control is poor in Black patients, leading to higher rates of renal failure and CV events. However, with the exception of hypertension, there is paucity in data demonstrating similar results within transplant recipients. Recent analyses conducted within our transplant program, indicate that CVD risk factors, especially diabetes, are poorly controlled in Black recipients, which likely impacts graft loss. Since these data were collected in a retrospective manner, larger analyses are needed to validate these exploratory findings.
This pilot study is to:
- Determine if the study is feasible, as measured by the proportions of enrolled to approached and completed to enrolled.
- Measure and compare, at baseline versus the end of the intervention, the medication safety events, including the number of medication errors, medication non-adherence and medication side effects, in patients enrolled in the study
- Measure and compare, at baseline versus the end of the intervention, CVD risk factor control, including hypertension, diabetes and dyslipidemia, in patients enrolled in the study
- Measure and compare, at baseline versus the end of the intervention, patient reported survey results, in patients enrolled in the study
- Determine if the impact of the intervention is more pronounced in Black recipients, as compared to non-Black recipients
Přehled studie
Postavení
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Medical University of South Carolina
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- At least 18 years of age and able to give informed consent.
- Received a first or repeat cadaveric or living donor renal transplant.
- Patient has adequate graft function, defined as an estimated glomerular filtration rate (GFR) of at least 20 mL/min, using the 4-variable Modification of Diet in Renal Disease (MDRD) equation.
- Patient is at least one year post transplant.
- Patient has documented hypertension, defined as a sitting blood pressure of at least 140/90 mmHg or receiving any anti-hypertensive therapy.
- Patient has documented diabetes mellitus, defined as a hemoglobin A1c of at least 6.5% or receiving any anti-glycemic medications.
- Willing to comply with all study visits.
Exclusion Criteria:
- Biopsy proven acute rejection episode that occurred within the past month.
- Patients who have received an organ transplant other than a kidney.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in blood pressure values from baseline to end of study
Časové okno: 6 months
|
Blood pressure will be assessed using clinic measurements, taken three times, five minutes apart in the same arm and averaged.
|
6 months
|
|
Change in HBA1C values from baseline to end of study
Časové okno: 6 months
|
6 months
|
|
|
Change in lipid values from baseline to end of study
Časové okno: 6 months
|
6 months
|
|
|
Medication adherence by comparing medication possession ratios (MPR) for the six months prior to enrollment compared to six months during the intervention
Časové okno: 1 year
|
1 year
|
|
|
Patient self-reported medication adherence at baseline compared to end of study.
Časové okno: 6 months
|
The Morisky 8-item adherence score will be compared from baseline to end of study.
|
6 months
|
|
Number of medication errors assessed at baseline and compared to errors at 6 months
Časové okno: 6 months
|
6 months
|
|
|
Medication side effects at baseline compared to end of study.
Časové okno: 6 months
|
The Memphis side effect scale will be used to compare side effects from baseline to end of study.
|
6 months
|
|
Patient reported survey results regarding self-care and health knowledge from baseline to end of study
Časové okno: 6 months
|
6 months
|
|
|
Patient reported survey results regarding psychosocial status from baseline to end of study
Časové okno: 6 months
|
6 months
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- Pro00051804
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .